Prosecution Insights
Last updated: November 20, 2026
Application No. 18/599,623

DEUTERATED INFIGRATINIB COMPOUNDS

Final Rejection §103
Filed
Mar 08, 2024
Priority
Mar 08, 2023 — provisional 63/489,168
Examiner
ELENISTE, PIERRE PAUL
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Qed Therapeutics Inc.
OA Round
2 (Final)
35%
Grant Probability
At Risk
3-4
OA Rounds
11m
Est. Remaining
66%
With Interview

Examiner Intelligence

Grants only 35% of cases
35%
Career Allowance Rate
34 granted / 97 resolved
-24.9% vs TC avg
Strong +31% interview lift
Without
With
+31.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
37 currently pending
Career history
145
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
47.7%
+7.7% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
24.6%
-15.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 97 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Withdrawn Grounds of Rejection The rejection of claim 1 under 35 U.S.C. 112(b), is withdrawn due to the claim amendments. Claim Objections Claim 1 is objected to because of the following informalities: the structure of the compound of Formula I is blurry, especially at the piperazine ring, wherein the various X-substituents are very blurry. Appropriate correction is required. New Grounds of Rejection Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or non- obviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 95-98, 101, 103, 105, 107-110, 113, 115, and 117 are rejected under 35 U.S.C. 103 as being unpatentable over Suzie Ribeiro WO 2015/087283 A1 (IDS, 07/21/2026) in view of Adam Morgan WO 2014/028595 A1, Harbeson et al., US PG-PUB 2010/0221221 A1. Ribeiro (page 1, line 7-9) teaches solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)- phenylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. Ribeiro (page 1, line 20-22) teaches the compound of Formula I is a protein kinase inhibitor and is useful in the treatment of proliferative diseases mediated by protein kinases. Ribeiro (page 1, line 20-22) further teaches the compound inhibits FGFR1, FGFR2, FGFR3, FGFR4, which is comparable to the claimed non-deuterated compound infigratinib (specification, [0041]). Ribeiro, PNG media_image1.png 106 372 media_image1.png Greyscale however, does not explicitly teach compound of Formula I is deuterated. Morgan (page 3, [9]; page 32, claim 16; page 3, [9]) teaches ponatinib (AP-24534), a protein kinase inhibitor and demonstrates potential as an inhibitor to VEGFR and FGFR. Morgan (page 2, [6]-[7]) teaches that replacement of hydrogen atoms with deuterium may improve the metabolic stability of a compound by slowing metabolic degradation and reducing the formation of undesirable metabolites. Morgan (page 2, [6]-[7]) further added that such improvement can enhance ADME properties and may improve efficacy, safety, and tolerability of a compound. PNG media_image2.png 612 1436 media_image2.png Greyscale For example, Morgan (page 30, claim 1; page 31, claim 13) discloses compounds of Formula I, wherein one or more hydrogen atoms on the piperazine moiety are replaced with deuterium atoms. This suggests that the deuterated piperazine moiety is critical for the compound’s inhibitory potency. This approach is further supported by Harbeson (abstract; [0003] and [0008] page 1, [0002] and [0008]-[0010]; pages 19, [0213]) who teaches the same concept of deuterating the piperazine moiety of imatinib, a protein kinase inhibitor. PNG media_image3.png 525 591 media_image3.png Greyscale Given that both Morgan and Harbeson disclose protein kinase inhibitors containing piperazine moieties and teach deuterium substitution as a means of modifying ADME and metabolic properties. Therefore, it would be obvious to a person of ordinary skill in the art (POSITA) to recognize that deuteration of piperazine moiety as a recognized strategy for improving metabolic, stability, efficacy, safety, and tolerability. Therefore, a POSITA would have been motivated to replace one or more hydrogen atoms on the piperazine moiety of Ribeiro’s compound with deuterium in view of Morgan and Harbeson’s disclosure with reasonable expectation that the such modification would enable the compound to not only retain its kinase inhibitory activity but also to improve its ADME and metabolic characteristics. Subject Matter Free of the Art of Record The subject matter of claims 99-100, 102, 104, 106, 111-112, 114, 116, and 118 is free of the art of record. The closest prior art is Suzie Ribeiro WO 2015/087283 A1, in view of Adam Morgan WO 2014/028595 A1 and Harbeson et al., US PG-PUB 2010/0221221 A1. Although the combined teachings of Ribeiro in view of Morgan and Harbeson teach deuteration of the piperazine moiety of compound, 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, the prior art fails to teach or suggest deuteration of the ethyl substituent on the piperazine group. Therefore, there is no motivation for a POSITA to modify the teaching of prior art to arrive at the claimed compound. The instant application is not allowable until the 103 rejection is overcome. Claims 99-100, 102, 104, 106, 111-112, 114, 116, and 118 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Claims 1, 95-98, 101, 103, 105, 107-110, 113, 115, and 117 are rejected. Claims 1, 99-100, 102, 104, 106, 111-112, 114, 116, and 118 are objected. No claims are allowed. Applicant's submission of an information disclosure statement under 37 CFR 1.97(c) with the timing fee set forth in 37 CFR 1.17(p) on July 21, 2026 prompted the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 609.04(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PIERRE PAUL ELENISTE whose telephone number is (571)270-0589. The examiner can normally be reached Monday - Friday 8:00 am - 5:00 pm (EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JAMES H ALSTRUM-ACEVEDO can be reached at (571) 272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /P.P.E./Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/ Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Mar 08, 2024
Application Filed
Apr 21, 2026
Non-Final Rejection mailed — §103
Jul 21, 2026
Response Filed
Oct 21, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766129
TOPICAL ANTI-INFLAMMATORY AND ANALGESIC COMPOSITIONS AND METHODS OF USE
2y 4m to grant Granted Oct 20, 2026
Patent 12758648
POLYOXAZOLINE-LIPID CONJUGATES AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME
2y 11m to grant Granted Oct 13, 2026
Patent 12753155
METHODS OF COUPLING A CARBON CONTAINING MOIETY TO AN AMINE CONTAINING MOIETY
3y 0m to grant Granted Oct 06, 2026
Patent 12747206
BIOACTIVE PHYTOCHEMICALS IN ZIZYPHUS AND GUARANA
5y 3m to grant Granted Sep 29, 2026
Patent 12728115
Compositions and Methods for Monitoring, Diagnosis, Detection and Treatment of Cancer
4y 4m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
35%
Grant Probability
66%
With Interview (+31.4%)
3y 7m (~11m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 97 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month